The clinically approved ROCK inhibitor, fasudil, suppresses Aβ production in neurons [33,35] and reduces the levels of phosphorylated tau and tau oligomers [34], making ROCK an interesting target in the search for AD treatment. Here, MAPT is linked to Alzheimer disease.